Recent Updates
Recently added Catalysts
COLL

Collegium to Host Conference Call to Discuss Third Quarter 2018 Financial Results and Provide Corporate Update

Key Takeaway: STOUGHTON, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 8, 2018 at 4:30 p.m. Eastern Time.  The Company will discuss its financial r

Full Press Release Details

STOUGHTON, Mass., Oct. 17, 2018 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) announced today that the Company will host a conference call and live audio webcast on Thursday, November 8, 2018 at 4:30 p.m. Eastern Time.  The Company will discuss its financial results and provide a corporate update.
Conference Call Information:
To access the conference call, please dial (888) 698-6931 (U.S.) or (805) 905-2993 (International) and refer to Conference ID: 178-3678.  An audio webcast will be accessible from the Investor Relations section of the Company’s website: http://www.collegiumpharma.com/.  An archived webcast will be available on the Company’s website approximately two hours after the event.
About Collegium Pharmaceutical, Inc.
Collegium is a specialty pharmaceutical company focused on becoming the leader in responsible pain management by developing and commercializing innovative and differentiated products for people suffering from pain and our communities.
Xtampza® ER is Collegium’s first product utilizing the DETERx technology platform. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone approved by the FDA for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Last updated: Oct 17, 2018